Response Genetics, Inc (RGDXQ)
Response Genetics, Inc operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Los Angeles, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $3,873. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -111.9%. Its beta of 4.72 implies it has historically moved more than the broad market.
Response Genetics, Inc., a life sciences company founded in Los Angeles, California, in 1999 (originally Bio Type, Inc., before its rebranding in August 2000), focuses on creating, advancing, and commercializing pharmacogenomic tests. These diagnostic tools are crucial for informing cancer treatment decisions by assessing specific indicators within tumor tissue samples that predict a patient's response to therapy. The company provides an extensive array of testing services, primarily through its ResponseDX suite, covering various cancers such as non-small cell lung, colorectal, gastric, gastroesophageal, melanoma, thyroid, breast, and glioma, in addition to a Tissue of Origin test. Beyond these existing solutions, Response Genetics is committed to expanding its diagnostic offerings to encompass other tumor types, while also delivering both the technical execution and professional interpretation components of its testing services. Operating globally, with a significant presence in the United States and Europe, Response Genetics serves a wide range of clients including community oncologists, pathologists, medical practices, hospitals, and pharmaceutical enterprises, primarily through its internal sales force.
Response Genetics, Inc is most often compared with the following Healthcare names: